/ /

  • linkedin
  • Increase Font
  • Sharebar

    Should HPV screening intervals be extended for some women?

    COG-SpecialDelivery-Issue_2641.jpg

    A Dutch study suggests that extending intervals for human papillomavirus (HPV) testing beyond 5 years—with risk stratification—may be appropriate in some women. Published in BMJ, the findings are from the POBASCAM trial, which reflected 14 years of follow up on HPV- and/or cytology-negative participants.

    The randomized cohort included 43,339 women aged 29 to 61 who were randomly assigned to HPV and cytology co-testing (intervention) or cytology testing alone (control).  The women underwent cervical cancer screening once every 5 years for 3 rounds and were managed based on the test results.

    Related: The latest on HPV prevention

    In the Netherlands, cytological-based cervical cancer screening is offered free to women aged 30 to 60 at 5-year intervals. Beginning in 2017, the interval will be extended to 10 years for HPV-negative women aged ≥40.  Under the current program, the documented cumulative 5-year risk of cervical intraepithelial neoplasia (CIN) 3+ after a negative screen is <1%. In other countries, such as Australia, Italy, New Zealand, and UK, women are screened every 2 to 3 years and there the interval is being expanded to 5 or 7 years.

    The Dutch investigators looked at cumulative incidence of cervical cancer and CIN grade 3 or worse (CIN3+) and estimated in HPV-positive women reductions in CIN3+ incidence after negative cytology, HPV type 16/18 genotyping, and/or repeat cytology. They found that the cumulative incidence of CIN3+ among HPV-negative women was similar to that in women with negative cytology who had undergone 2 rounds of screening (0.09% and 0.69%, respectively). Cervical cancer and CIN3+ risk ratios were 0.97 (95% confidence interval [CI] 0.41 to 2.31, P=0.95) and 0.62 to 1.09, P=0.17) in the two groups, respectively.

    In HPV-negative women aged ≥40, compared with younger women, CIN3+ incidence was 72.2% lower (95% CI 61.6% to 79.9%, P<0.01). There was no significant association between cervical cancer incidence and age. In HPV-positive women with negative cytology, HPV 16/18 genotyping, and/or repeat cytology, CIN3+ incidence was 10.4 times higher than among HPV-negative women (95% CI 5.9 to 18.4).

    The authors concluded that the low long-term incidences of cervical cancer and CIN3+ among HPV-negative women who were studied support extension of the cervical cancer screening interval beyond 5 years in women aged ≥40. Risk stratification should be incorporated into HPV-based programs with intervals >5 years, they said, because of the finding that risk of CIN3+ is at least fivefold higher in HPV-positive women with subsequent negative cytology HPV16/18 genotyping, and/or repeat cytology than in HPV-negative women. 

    NEXT: How azithromycin prophylaxis before cesaren can reduce postop infection

    Judith M. Orvos, ELS
    Judith M. Orvos, ELS, is a a BELS-certified medical writer and editor and an editorial consultant for Contemporary OB/GYN.
    Miranda Hester
    Ms. Hester is Content Specialist with Contemporary OB/GYN and Contemporary Pediatrics.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    Latest Tweets Follow